Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled Copenhagen Stock Exchange:ORPHA arimoclomol |
All times are GMT -5. The time now is 10:34 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.